Medscape

Mavacamten in Hypertrophic Cardiomyopathy: Reasons for Both Optimism and Caution

The novel first-in-class drug mavacamten looks like an advance for patients with symptomatic hypertrophic cardiomyopathy. But there are reasons for caution. At the American College of Cardiology (ACC) ...
Healio

Optimizing mavacamten for treatment of obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
TCTMD

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

In patients with hypertrophic cardiomyopathy (HCM), the first-in-class cardiac myosin inhibitor mavacamten (MyoKardia), on top of medical therapy, significantly improved hemodynamics, functional ...
The American Journal of Managed Care

Real-World Risks of Mavacamten Use for Obstructive Hypertrophic Cardiomyopathy

Mavacamten treatment in oHCM patients led to new atrial fibrillation/flutter and heart failure, with frequent acute care episodes within months. Nearly half of the patients required dose adjustments, ...
TCTMD

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

WASHINGTON, DC (UPDATED)—Among patients with obstructive hypertrophic cardiomyopathy (HCM) who are candidates for surgical or interventional septal reduction therapy (SRT) despite being on maximally ...
Business Wire

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...
Healio

Mavacamten may improve structural abnormalities of obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Mavacamten improved left ventricular hypertrophy, decreased measures of heart stiffness and restored normal ...
Nasdaq

Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70th ...

New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of ...
The American Journal of Managed Care

Efficacy and Safety of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results of the EXPLORER-HCM Study

This AJMC® Clinical Brief provides key information regarding the EXPLORER-HCM study (NCT03470545), the results of which were originally presented by Iacopo Olivotto, MD, at the European Society of ...
The New England Journal of Medicine

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...
Business Wire

Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70 th ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that data from multiple studies across the company’s clinical program investigating mavacamten in patients with ...